Teva, Cephalon Sue FDA Over Generic Provigil Exclusivity

Law360, Chicago (April 4, 2012, 5:25 PM EDT) -- Teva Pharmaceuticals USA Inc. and Cephalon Inc. sued the U.S. Food and Drug Administration in Washington federal court Tuesday seeking to bar the agency from robbing Teva of the marketing exclusivity period they say it earned through patent certifications for its generic version of Cephalon's blockbuster sleep disorder drug Provigil.

Cephalon — a wholly owned, indirect subsidiary of Teva Ltd. — and Teva allege that despite the 180-day exclusivity period Teva is entitled to thanks to the patent certifications included in the abbreviated new drug application...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

TEVA PHARMACEUTICALS USA, INC. et al v. SEBELIUS et al


Case Number

1:12-cv-00512

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Richard W. Roberts

Date Filed

April 2, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.